Reviews on Long COVID: A scope of the literature:Update July 2024

• For this update, we identified 33 published reviews and 43 review protocols for Long COVID. • The number of reviews (n=33) is fewer than in April 2024 (n=36), January 2024 (n=42), and October 2023 (n=46), but more than in July 2023 (n=31). • The largest category of reviews focused on treatment or rehabilitation (13/33), whereas the prevalence of symptoms or effects (n=7, for this update) was the largest category within all previous reports. • We identified four reviews on risk factors with or without prevalence, three on pathobiology or mechanisms, and two on prevention; the other four were on treatment with: prevalence (n=2), prevention (n=1), or risk factors (n=1). • We identified fewer protocols (n=43) than in the previous update (April 2024, n=63) and July 2023 (n=53), but a similar number to January 2024 (n=42) and October 2023 (n=44). • As in previous reports, the largest two categories of protocols focused on the prevalence of symptoms or effects (16/43), and treatment or rehabilitation (11/43). • Six protocols were focused on risk factors with or without prevalence, and four were on prevention; these numbers are similar to those in previous reports. Three protocols were on experiences of Long COVID with or without prevalence, and three protocols were on pathobiology; pathobiology and treatment; and prevalence and treatment.